Atea Pharmaceuticals, Inc. AVIR
Set alert
At close
Pre-market · Nov 2, 8:06 AM ET
- YTD
- +15.13%
- 1 year
- +25.69%
- Open
- 4.30
- Prev close
- 4.31
- Mkt cap
- 329.64M
- Vol
- 349.86K
- Avg vol
- 280.24K
- EPS
- -2.09
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.07
- High
- 4.32
- Forward P/E
- -2.12
- Beta
- 0.17
- Short ratio
- 14.25
- Inst. own
- 71.14%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 3.31
- 200-d avg
- 3.59
- 1y target
- 7.40
News
1 month ago seekingalpha.com
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of…
2 months ago defenseworld.net
BlackRock Inc. Makes New $40.55 Million Investment in Atea Pharmaceuticals, Inc. $AVIR
BlackRock Inc. purchased a new position in Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission.…
-
2 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
2 months ago seekingalpha.com
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Atea Pharmaceuticals Q2 Earnings Call Highlights
Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and…
2 months ago globenewswire.com
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV
2 months ago globenewswire.com
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral…
3 months ago benzinga.com
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.
-
3 months ago benzinga.com
Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir
In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL (Epclusa) at Week 24, encompassing SVR at 12 weeks…
3 months ago globenewswire.com
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful…
-
3 months ago benzinga.com
Atea Pharmaceuticals Initiates First-in-human Phase 1 Clinical Trial Of AT-587 For Hepatitis E Virus Infection
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
3 months ago globenewswire.com
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver…
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares…
-
4 months ago benzinga.com
Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus Infection
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North AmericaC-FORWARD and C-BEYOND Represent the…
4 months ago globenewswire.com
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the…
4 months ago zacks.com
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
4 months ago zacks.com
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
5 months ago seekingalpha.com
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR's BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV…
5 months ago globenewswire.com
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral…
5 months ago zacks.com
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts…
5 months ago globenewswire.com
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral…
5 months ago seekingalpha.com
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
5 months ago marketbeat.com
Atea Pharmaceuticals Q1 Earnings Call Highlights
Atea Pharmaceuticals NASDAQ: AVIR said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no…
5 months ago benzinga.com
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
-
5 months ago benzinga.com
Atea Pharmaceuticals Q1 EPS $(0.57) Beats $(0.59) Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.59) by 3.39 percent. This is a 42.5 percent decrease over losses of…
5 months ago globenewswire.com
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of…
6 months ago globenewswire.com
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral…
7 months ago benzinga.com
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX) and Atea Pharma (AVIR) among top-ranked.
-
7 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10
Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.
-
8 months ago benzinga.com
Atea Pharmaceuticals Q4 EPS $(0.57) Misses $(0.53) Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 42.5 percent decrease over losses…
-
8 months ago benzinga.com
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
-
10 months ago benzinga.com
Atea Pharmaceuticals Completes Enrollment Of Over 880 Treatment-naïve Patients In C-BEYOND Phase 3 Trial Of Fixed-dose Combination Bemnifosbuvir And Ruzasvir Compared To Sofosbuvir And Velpatasvir Regime For Hepatitis C Virus; Results Are Expected Mid-year 2026
In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWARD, a Phase 3 trial evaluating this same FDC regimen in 880 patients at approximately 120 clinical…
-
11 months ago benzinga.com
Atea Pharmaceuticals Q3 EPS $(0.53) Misses $(0.44) Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.44) by 20.45 percent. This is a 43.24 percent decrease over losses…
-
11 months ago benzinga.com
Earnings Scheduled For November 12, 2025
Earnings Scheduled For November 12, 2025
11 months ago benzinga.com
Atea Pharmaceuticals Earnings Preview
Atea Pharmaceuticals Earnings Preview
-
12 months ago benzinga.com
Atea Pharmaceuticals Released New Modeling Data Showing Its Bemnifosbuvir And Ruzasvir Combination Regimen Achieved Near-Complete Inhibition Of HCV Replication And Secretion, With A Predicted Cure Time Of 7–8 Weeks
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
-
1 year ago benzinga.com
Atea Pharma To Present New Data Supporting Combination Regimen Of Bemnifosbuvir As Potential For HCV Infection Treatment At The Liver Meeting 2025, AASLD
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
-
1 year ago benzinga.com
Atea Pharmaceuticals Q2 EPS $(0.44) Misses $(0.43) Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 8.33 percent increase over losses…
-
1 year ago benzinga.com
Atea Begins Global Late-Stage Trial of Oral Hepatitis C Drug Combo Aimed at Easier, Faster Cure
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
-
1 year ago benzinga.com
Atea Pharmaceuticals Q1 EPS $(0.40) Beats $(0.41) Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 46.67 percent increase over losses of…
-
1 year ago benzinga.com
Atea Pharmaceuticals Releases Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus, Including Confirmed 98% Sustained Virologic Response At 12 Weeks Post-Treatment After Short 8-Week Treatment Duration For Regimen
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for RegimenResults from Phase 1 Study Showed Low…
-
1 year ago benzinga.com
Atea Pharma Presents Results From Full Cohort Of Patients Enrolled In Phase 2 Study Evaluating Once-daily Combination Of BEM And RZR For Treatment Of Hepatitis C Virus
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for RegimenResults from Phase 1 Study Showed Low…
-
1 year ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and lowers the price target from $6.2 to $6.
1 year ago benzinga.com
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial
Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.
-
1 year ago benzinga.com
Atea Pharmaceuticals Q4 EPS $(0.40) Misses $(0.37) Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 14.89 percent increase over losses…